AstraZeneca has outlined its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The Big Pharma is applying its own discovery capabilities to the task and helping evaluate candidates identified by academic partners in China and the U.S.

As part of DARPA’s Pandemic Preparedness Platform program, AstraZeneca developed capabilities to discover antibodies against emerging viral threats. AstraZeneca first revealed it had joined the race to develop coronavirus-neutralizing antibodies several weeks ago, going on to say it had put more than 50 experts in fields such as virology and immunology on the case around the start of the month. Source: Fierce Biotech 8/4/2020